Edwards Lifesciences Corporation
EW
$75.15
-$0.74-0.98%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.90% | 8.23% | 4.15% | 0.48% | -3.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.90% | 8.23% | 4.15% | 0.48% | -3.35% |
| Cost of Revenue | 9.40% | 13.26% | 8.28% | 6.86% | 0.77% |
| Gross Profit | 7.52% | 7.01% | 3.16% | -1.03% | -4.33% |
| SG&A Expenses | 11.91% | 12.83% | 8.41% | 6.21% | 3.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 47.57% | -- | -187.27% | -200.00% | -200.00% |
| Total Operating Expenses | 10.35% | 11.96% | -1.24% | -3.21% | 0.47% |
| Operating Income | 2.01% | -0.59% | 18.32% | 9.59% | -11.42% |
| Income Before Tax | 15.23% | 12.65% | 4.00% | 1.60% | -16.84% |
| Income Tax Expenses | 14.60% | -0.39% | -21.43% | -19.71% | -32.81% |
| Earnings from Continuing Operations | 15.31% | 14.28% | 7.55% | 4.73% | -14.33% |
| Earnings from Discontinued Operations | 1,540.07% | 1,447.10% | 1,841.74% | 21.60% | 336.55% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 43.59% | 63.33% | 35.71% | 125.00% | -- |
| Net Income | 195.71% | 197.68% | 190.65% | 6.01% | -5.04% |
| EBIT | 2.01% | -0.59% | 18.32% | 9.59% | -11.42% |
| EBITDA | 2.14% | 0.09% | 16.99% | 9.34% | -10.10% |
| EPS Basic | 200.24% | 202.32% | 195.52% | 7.39% | -3.43% |
| Normalized Basic EPS | 6.43% | 4.44% | 21.85% | 12.75% | -7.33% |
| EPS Diluted | 200.81% | 203.73% | 196.77% | 7.54% | -3.03% |
| Normalized Diluted EPS | 6.65% | 4.61% | 22.11% | 13.02% | -7.05% |
| Average Basic Shares Outstanding | -1.85% | -1.48% | -1.16% | -1.27% | -1.64% |
| Average Diluted Shares Outstanding | -2.06% | -1.67% | -1.37% | -1.51% | -1.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |